Pfizer Booster Dose Restores Full Protection With High Effectiveness Against Covid-19
According to Xinhua, Pfizer and BioNTech reported Thursday that a large-scale study of their COVID-19 vaccine booster restored complete protection against the infection.
In a Phase 3 randomised controlled trial, a Pfizer-BioNTech booster dose was given to over 10,000 people aged 16 and above who had previously received the Pfizer-BioNTech primary two-dose series.
When compared to individuals who did not get a booster, it had a relative vaccination effectiveness of 95.6%.
These are the first effectiveness findings from any COVID-19 vaccination booster study that has been randomised and controlled.
According to Albert Bourla, Pfizer chairman and chief executive officer, “these results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease.”
source - the straits times
The US Food and Drug Administration approved booster shots for the Pfizer-BioNTech COVID-19 vaccine last month, allowing a single booster dose of the Pfizer-BioNTech vaccine to be administered at least 6 months after completion of the primary series to individuals 65 years of age and older, as well as individuals 18 to 64 years of age who have frequent institutional or occupational exposure to SARS-CoV-2.